Interestingly, treatment of Fra-2 transgenic mice with the antifibrotic compound nintedanib, currently approved for the management of SSc-associated ILD, was found to reduce dermal MVEC apoptosis and ameliorate capillary loss, all effects that were associated with the normalization of circulating VEGF [88]. This evidence concerns the gene VEGFA and systemic sclerosis.